Overcoming resistance to conventional drugs in Ewing sarcoma and identification of molecular predictors of outcome

Katia Scotlandi, Daniel Remondini, Gastone Castellani, Maria Cristina Manara, Filippo Nardi, Lara Cantiani, Mirko Francesconi, Mario Mercuri, Anna Maria Caccuri, Massimo Serra, Sakari Knuutila, Piero Picci

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Purpose: The improvement of Ewing sarcoma (EWS) therapy is currently linked to the discovery of strategies to select patients with poor and good prognosis and of modified treatment regimens. In this study, we analyzed the molecular factors governing EWS response to chemotherapy to identify genetic signatures to be used for risk-adapted therapy. Patients and Methods: Microarray technology was used for profiling 30 primary tumors and seven metastases of patients who were classified according to event-free survival. For selected genes, real-time polymerase chain reaction was applied in 42 EWS primary tumors as validation assay. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide test was used to evaluate in vitro drug sensitivity. Results: We identified molecular signatures that reflect tumor resistance to chemotherapy. Annotation analysis was applied to reveal the biologic functions that critically influenced clinical outcome. The prognostic relevance of glutathione metabolism pathway was validated. The expression of MGST1, the microsomal glutathione S-transferase (GST), was found to clearly predict EWS prognosis. MGST1 expression was associated with doxorubicin chemosensitivity. This prompted us to assess the in vitro effectiveness of 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX), a new anticancer agent that efficiently inhibits GST enzymes. Six cell lines were found to be sensitive to this new drug. Conclusion: Classification of EWS patients into high- and low-risk groups is feasible with restricted molecular signatures that may have practical value at diagnosis for selecting patients with EWS who are unresponsive to current treatments. Glutathione metabolism pathway emerged as one of the most significantly altered prognosis-associated pathway. NBDHEX is proposed as a new potential therapeutic possibility.

Original languageEnglish
Pages (from-to)2209-2216
Number of pages8
JournalJournal of Clinical Oncology
Volume27
Issue number13
DOIs
Publication statusPublished - May 1 2009

Fingerprint

Ewing's Sarcoma
Pharmaceutical Preparations
Glutathione Transferase
Glutathione
Therapeutics
Drug Therapy
Neoplasms
Antineoplastic Agents
Doxorubicin
Disease-Free Survival
Real-Time Polymerase Chain Reaction
Neoplasm Metastasis
Technology
Cell Line
Enzymes
Genes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Overcoming resistance to conventional drugs in Ewing sarcoma and identification of molecular predictors of outcome. / Scotlandi, Katia; Remondini, Daniel; Castellani, Gastone; Manara, Maria Cristina; Nardi, Filippo; Cantiani, Lara; Francesconi, Mirko; Mercuri, Mario; Caccuri, Anna Maria; Serra, Massimo; Knuutila, Sakari; Picci, Piero.

In: Journal of Clinical Oncology, Vol. 27, No. 13, 01.05.2009, p. 2209-2216.

Research output: Contribution to journalArticle

Scotlandi, K, Remondini, D, Castellani, G, Manara, MC, Nardi, F, Cantiani, L, Francesconi, M, Mercuri, M, Caccuri, AM, Serra, M, Knuutila, S & Picci, P 2009, 'Overcoming resistance to conventional drugs in Ewing sarcoma and identification of molecular predictors of outcome', Journal of Clinical Oncology, vol. 27, no. 13, pp. 2209-2216. https://doi.org/10.1200/JCO.2008.19.2542
Scotlandi, Katia ; Remondini, Daniel ; Castellani, Gastone ; Manara, Maria Cristina ; Nardi, Filippo ; Cantiani, Lara ; Francesconi, Mirko ; Mercuri, Mario ; Caccuri, Anna Maria ; Serra, Massimo ; Knuutila, Sakari ; Picci, Piero. / Overcoming resistance to conventional drugs in Ewing sarcoma and identification of molecular predictors of outcome. In: Journal of Clinical Oncology. 2009 ; Vol. 27, No. 13. pp. 2209-2216.
@article{2ef1ab910d244de49abe068232132f3d,
title = "Overcoming resistance to conventional drugs in Ewing sarcoma and identification of molecular predictors of outcome",
abstract = "Purpose: The improvement of Ewing sarcoma (EWS) therapy is currently linked to the discovery of strategies to select patients with poor and good prognosis and of modified treatment regimens. In this study, we analyzed the molecular factors governing EWS response to chemotherapy to identify genetic signatures to be used for risk-adapted therapy. Patients and Methods: Microarray technology was used for profiling 30 primary tumors and seven metastases of patients who were classified according to event-free survival. For selected genes, real-time polymerase chain reaction was applied in 42 EWS primary tumors as validation assay. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide test was used to evaluate in vitro drug sensitivity. Results: We identified molecular signatures that reflect tumor resistance to chemotherapy. Annotation analysis was applied to reveal the biologic functions that critically influenced clinical outcome. The prognostic relevance of glutathione metabolism pathway was validated. The expression of MGST1, the microsomal glutathione S-transferase (GST), was found to clearly predict EWS prognosis. MGST1 expression was associated with doxorubicin chemosensitivity. This prompted us to assess the in vitro effectiveness of 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX), a new anticancer agent that efficiently inhibits GST enzymes. Six cell lines were found to be sensitive to this new drug. Conclusion: Classification of EWS patients into high- and low-risk groups is feasible with restricted molecular signatures that may have practical value at diagnosis for selecting patients with EWS who are unresponsive to current treatments. Glutathione metabolism pathway emerged as one of the most significantly altered prognosis-associated pathway. NBDHEX is proposed as a new potential therapeutic possibility.",
author = "Katia Scotlandi and Daniel Remondini and Gastone Castellani and Manara, {Maria Cristina} and Filippo Nardi and Lara Cantiani and Mirko Francesconi and Mario Mercuri and Caccuri, {Anna Maria} and Massimo Serra and Sakari Knuutila and Piero Picci",
year = "2009",
month = "5",
day = "1",
doi = "10.1200/JCO.2008.19.2542",
language = "English",
volume = "27",
pages = "2209--2216",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "13",

}

TY - JOUR

T1 - Overcoming resistance to conventional drugs in Ewing sarcoma and identification of molecular predictors of outcome

AU - Scotlandi, Katia

AU - Remondini, Daniel

AU - Castellani, Gastone

AU - Manara, Maria Cristina

AU - Nardi, Filippo

AU - Cantiani, Lara

AU - Francesconi, Mirko

AU - Mercuri, Mario

AU - Caccuri, Anna Maria

AU - Serra, Massimo

AU - Knuutila, Sakari

AU - Picci, Piero

PY - 2009/5/1

Y1 - 2009/5/1

N2 - Purpose: The improvement of Ewing sarcoma (EWS) therapy is currently linked to the discovery of strategies to select patients with poor and good prognosis and of modified treatment regimens. In this study, we analyzed the molecular factors governing EWS response to chemotherapy to identify genetic signatures to be used for risk-adapted therapy. Patients and Methods: Microarray technology was used for profiling 30 primary tumors and seven metastases of patients who were classified according to event-free survival. For selected genes, real-time polymerase chain reaction was applied in 42 EWS primary tumors as validation assay. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide test was used to evaluate in vitro drug sensitivity. Results: We identified molecular signatures that reflect tumor resistance to chemotherapy. Annotation analysis was applied to reveal the biologic functions that critically influenced clinical outcome. The prognostic relevance of glutathione metabolism pathway was validated. The expression of MGST1, the microsomal glutathione S-transferase (GST), was found to clearly predict EWS prognosis. MGST1 expression was associated with doxorubicin chemosensitivity. This prompted us to assess the in vitro effectiveness of 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX), a new anticancer agent that efficiently inhibits GST enzymes. Six cell lines were found to be sensitive to this new drug. Conclusion: Classification of EWS patients into high- and low-risk groups is feasible with restricted molecular signatures that may have practical value at diagnosis for selecting patients with EWS who are unresponsive to current treatments. Glutathione metabolism pathway emerged as one of the most significantly altered prognosis-associated pathway. NBDHEX is proposed as a new potential therapeutic possibility.

AB - Purpose: The improvement of Ewing sarcoma (EWS) therapy is currently linked to the discovery of strategies to select patients with poor and good prognosis and of modified treatment regimens. In this study, we analyzed the molecular factors governing EWS response to chemotherapy to identify genetic signatures to be used for risk-adapted therapy. Patients and Methods: Microarray technology was used for profiling 30 primary tumors and seven metastases of patients who were classified according to event-free survival. For selected genes, real-time polymerase chain reaction was applied in 42 EWS primary tumors as validation assay. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide test was used to evaluate in vitro drug sensitivity. Results: We identified molecular signatures that reflect tumor resistance to chemotherapy. Annotation analysis was applied to reveal the biologic functions that critically influenced clinical outcome. The prognostic relevance of glutathione metabolism pathway was validated. The expression of MGST1, the microsomal glutathione S-transferase (GST), was found to clearly predict EWS prognosis. MGST1 expression was associated with doxorubicin chemosensitivity. This prompted us to assess the in vitro effectiveness of 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX), a new anticancer agent that efficiently inhibits GST enzymes. Six cell lines were found to be sensitive to this new drug. Conclusion: Classification of EWS patients into high- and low-risk groups is feasible with restricted molecular signatures that may have practical value at diagnosis for selecting patients with EWS who are unresponsive to current treatments. Glutathione metabolism pathway emerged as one of the most significantly altered prognosis-associated pathway. NBDHEX is proposed as a new potential therapeutic possibility.

UR - http://www.scopus.com/inward/record.url?scp=65549117869&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65549117869&partnerID=8YFLogxK

U2 - 10.1200/JCO.2008.19.2542

DO - 10.1200/JCO.2008.19.2542

M3 - Article

C2 - 19307502

AN - SCOPUS:65549117869

VL - 27

SP - 2209

EP - 2216

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 13

ER -